中国血吸虫病防治杂志 ›› 2021, Vol. 33 ›› Issue (6): 553-.

• 专家论坛 • 上一篇    下一篇

RTS, S/AS01疟疾疫苗大规模现场应用 可能面临的挑战

冯高谦1, 2*   

  1. 1 澳大利亚伯内特医学研究所(墨尔本 3004);2 墨尔本大学医学院(墨尔本 3052)
  • 出版日期:2022-01-12 发布日期:2022-01-12
  • 作者简介:冯高谦,博士,现任澳大利亚Burnet Institute高级研究员、墨尔本大学医学院荣誉研究员,兼任WHO疟疾快速诊断试剂预评估专家、《Frontiers in Cellular and Infection Microbiology》副编委、《中国寄生虫学与寄生虫病杂志》青年编委。主要研究方向为疟原虫感染与免疫,曾主持或参与多个澳大利亚国家级科研项目以及PATH-MIV和比尔及梅琳达·盖茨基金会等国际项目。在《Science Translational Medicine》、《Science Advances》、《Immunity》、《Nature Communications》、《BMC Medicine》、《The Journal of Infectious Diseases》等学术期刊发表论文26篇,H 指数20。

Potential challenges for large⁃scale uses of RTS, S/AS01 vaccine in malaria⁃endemic areas

FENG Gao⁃qian1,2*   

  1. 1 Burnet Institute, Melbourne 3004, Australia; 2 Department of Medicine, The University of Melbourne, Melbourne 3052, Australia
  • Online:2022-01-12 Published:2022-01-12

摘要: RTS, S/AS01疟疾疫苗获得WHO批准大规模应用是人类抗击寄生虫感染史上的一个里程碑,然而 RTS, S/AS01 疫苗并非完美。本文从免疫学角度探讨了RTS, S/AS01疟疾疫苗存在的不足以及下一代疟疾疫苗研发可能面临的挑战。  

关键词: 疟疾, RTS, S/AS01疫苗, 保护性免疫

Abstract: RTS, S/AS01 vaccine has recently been recommended by the WHO for large⁃scale uses in malaria⁃endemic areas, which is a milestone in the history of the fight against parasitic infections. Nevertheless, RTS, S/AS01 vaccine is not perfect. Hereby, the shortages of RTS, S/AS01 malaria vaccine were discussed, and the potential challenges during the research and development of next⁃generation malaria vaccines were analyzed.

Key words: Malaria, RTS,S/AS01 vaccine, Protective immunity

中图分类号: